Insulet (NSDQ:PODD) and Dexcom (NSDQ:DXCM) yesterday floated a joint promotion aimed at luring users of the Animas insulin pump after Johnson & Johnson (NYSE:JNJ) bails out of the insulin pump biz.
The companies are hoping to chip off a piece of the diabetes market from Medtronic (NYSE:MDT), to which J&J has offered to help some 90,000 Animas patients transfer (J&J is also evaluating another of its diabetes businesses, LifeScan, which makes the OneTouch line of blood glucose monitoring products).
Last week Billerica, Mass.-based Insulet said it would offer a “Welcome Program” featuring a free Omnipod tubeless insulin delivery system, built-in blood glucose meter and 30 days of supplies at not cost to the user.
Today Insulet and Dexcom added a $200 gift card for purchasing the latter’s G5 mobile continuous glucose monitor.
“We created this program to provide a way for Animas users to experience the freedom of the Omnipod system with the peace of mind of Dexcom’s market-leading CGM,” Insulet chief commercial officer Bret Christensen said in prepared remarks. “Managing diabetes is a very personal decision and we strongly support an individual’s right to choice when it comes to their diabetes management. This partnership is just one example of our commitment to support people with diabetes today and over the long term.”
“Dexcom is excited to partner with Insulet to offer this special promotion,” added Dexcom CCO Rick Doubleday. “This provides Animas users the opportunity to upgrade to our best-selling Dexcom G5 mobile CGM and have easier access to the only tubeless pump system in the U.S.”
